MCK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
McKesson is not a strong buy right now for a Beginner investor focused on long-term investing with $50,000-$100,000 to deploy. The stock has solid fundamental analyst support and a durable business model, but the current technical setup is mixed to weak, insider selling is rising, congress trading shows net selling, and there is no fresh news catalyst to support immediate upside. Since the user is impatient and does not want to wait for a better entry, my direct view is to hold off on buying today and wait for a cleaner pullback or a stronger breakout above resistance.
MCK is trading pre-market at 757, very close to the pivot level of 759.543. Momentum is mixed: MACD histogram is positive and expanding, which is constructive, but RSI_6 at 45.168 is neutral, not indicating strong buying pressure. The moving average structure is bearish with SMA_200 > SMA_20 > SMA_5, which suggests the shorter-term trend is still lagging the long-term trend. Key levels matter here: immediate support is 741.816 and resistance is 777.271. Overall, the trend is not bad enough to avoid entirely, but it is not an attractive entry for an impatient buyer at current levels.
["Analysts remain broadly positive, with multiple Buy/Outperform ratings still in place.", "UBS raised its target to $1,050 and said the initial FY27 outlook looks good enough.", "BofA said FY27 guidance and long-range plan reiteration were clear positives.", "William Blair initiated with Outperform, citing a durable competitive moat and specialty-led growth upside.", "The business benefits from structural healthcare demand and demographic tailwinds."]
["No news in the recent week, so there is no fresh event-driven catalyst.", "Several analysts lowered price targets after recent results, showing some caution on near-term upside.", "Insiders are selling, with selling activity up 144.45% over the last month.", "Congress trading data shows 1 sale and 0 purchases in the last 90 days, which is a negative sentiment signal.", "Stock trend model suggests weak near-term performance, including roughly -3.2% over the next month.", "Technicals show bearish moving averages, limiting near-term entry quality."]
Latest quarter financial data was not provided due to a snapshot error, so I cannot assess revenue or earnings trends directly. However, analyst commentary around the recent quarter suggests McKesson had a mixed Q4/Q1-style print, while FY27 guidance and the long-range plan were viewed as supportive. Based on the available commentary, the company still appears to be growing at a steady, mature pace rather than showing explosive acceleration.
Analyst sentiment remains positive overall, but target cuts have been more common than raises recently. Recent updates: Citi cut target to $945 but kept Buy; UBS raised target to $1,050 and kept Buy; Deutsche Bank cut to $875 and kept Buy; Baird cut to $941 and kept Outperform; JPMorgan cut to $1,015 and kept Overweight; Evercore cut to $850 and kept Outperform; BofA cut to $900 and kept Buy. Wall Street pros still favor the stock, citing moat, specialty growth, and supportive long-term outlook, but the cons side is clear: recent results were mixed, peer multiple compression pressured targets, and near-term enthusiasm has cooled.
